In AITL multistep tumor model, TET2 and/or DNMT3A mutations occurred first, followed by specification into the Tfh lineage guided by expression of the RHOAG17V mutant and enhanced by hyper activation of the T-cell receptor signaling pathway (39). This evidence concerns the gene TET2 and angioimmunoblastic T-cell lymphoma.